Venquis Therapeutics develops novel small molecule direct protein degraders using its CIPD platform for oncology and other diseases. This technology identifies mechanistically differentiated degraders that directly bind the protein of interest for cellular elimination. The approach focuses on achieving mutant-selective targeting, degrading driver-mutant proteins while sparing corresponding wild-type versions.
Funding
$280K raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Many cancers and degenerative diseases are driven by mutant proteins that are difficult to target with traditional therapies. These proteins often lack well-defined binding pockets for small molecule drugs, or their inhibition leads to unacceptable off-target effects. This presents a significant challenge in developing effective treatments for these diseases.
Solution
This company is developing a new class of small molecule drugs designed to selectively degrade disease-causing mutant proteins. Their approach leverages targeted protein degradation, inducing the removal of specific proteins from cells. By selectively eliminating these mutant proteins, the company aims to develop therapeutics that address the root cause of the disease while minimizing off-target effects. This strategy offers a potential solution for previously undruggable targets in oncology and degenerative diseases.
Target Audience
The primary target audience includes pharmaceutical companies seeking novel drug candidates for oncology and degenerative diseases, as well as clinical researchers focused on targeted protein degradation.
Features
- Development of small molecule degraders that selectively bind to and eliminate mutant proteins.
- Focus on oncology and degenerative diseases with unmet medical needs.
- Novel approach to target proteins lacking traditional binding pockets.
- Preclinical validation of degrader efficacy and selectivity.